GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

Bildnachweis: Trophic Communications, VC Magazin, Pixabay. With over three decades in strategic communications and a track record with leaders like BioNTech and Tubulis, Gretchen Schweitzer brings ...

NHS England's collaboration with BioNTech is crucial in discovering individuals who may benefit from the trial.

“Stratus,” originally known as Variant XFG, is the second most prominent strain of COVID in the United States. According to ...

26 April 2024 New claim from GlaxoSmithKline is latest in litany of lawsuits against rivals | US lawsuit, potentially worth ...

GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

In its new guidelines, the American Heart Association says not all ultraprocessed foods are so bad — such as whole grain breads, low-sugar yogurts, tomato sauces, and nut or bean-based spreads. The ...

CureVac and GSK will receive $740 million and single-digit royalties on COVID-19 vaccine sales in the U.S. going forward.

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 million plus royalties to settle US legal disputes over Covid-19 vaccines, ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...